Uncategorized
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2016, along with a general business update. Aerie Highlights and Outlook Rhopressa™ (netarsudil ophthalmic solution) 0.02% NDA (ne